Neuronetics—a company focused on designing, developing and marketing products that improve the quality of life for patients with psychiatric disorders—has announced that Stephen Furlong will become its new chief financial officer and Secretary, replacing Peter Donato.

The company’s first commercial product—the NeuroStar Advanced Therapy System—is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Furlong is a financial executive with nearly two decades of medical technology experience. He most recently served as senior vice president of finance and corporate secretary at Metabolon, a global leader in metabolomics, a phenotyping technology for advancing biomarker discovery, diagnostic testing and precision medicine. Prior to joining Metabolon, he served as chief financial officer of Rapid Micro Biosystems, which manufactures and distributes innovative products for fast, accurate and efficient detection of microbial contamination.

Chris Thatcher, president and CEO of Neuronetics, comments: “We are very excited to have Steve join Neuronetics as CFO. Steve brings valuable and highly relevant financial leadership experience with fast growing companies in the medical technology industry to Neuronetics and will be a valuable addition to the senior management team as we look to continue to drive the adoption of NeuroStar Advanced Therapy and expand our market leadership position.”